SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Hence then, the article about innovent and hutchmed jointly announce nda acceptance in china for sintilimab combination with fruquintinib for the treatment of advanced renal cell carcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma )
Also on site :
- This Airline Just Upgraded Premium Economy With Full Privacy Screens, Electric Recline, and Wireless Charging
- France Launches Global Initiatives to Support Independent Cinema and Establish Framework for Alliance of State Film Commissions: Lumiere Summit
- Nuclear-capable warship that capsized when launched finally joins North Korea’s fleet